Skip to main content

Table 1 Summary of patient baseline characteristics

From: A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia

Characteristics

PBO

LY40

LY80

RIS

TOTAL

Overall p-Value

ITT Overall Population

N = 295

N = 292

N = 280

N = 142

N = 1009

 

Age, years, mean (SD)

39.8 (11.4)

39.6 (11.5)

40.5 (11.5)

40.3 (11.1)

40.0 (11.5)

0.771

Gender, male, n (%)

181 (61.4)

196 (67.1)

183 (65.4)

87 (61.3)

647 (64.1)

0.422

Ethnicity, n (%)

     

0.612

 Hispanic or Latino

13 (4.4)

11 (3.8)

15 (5.4)

9 (6.3)

48 (4.8)

 

 Not Hispanic or Latino

282 (95.6)

281 (96.2)

265 (94.6)

133 (93.7)

961 (95.2)

 

Race, n (%)

     

0.899

 American Indian or Alaska Native

1 (0.3)

0 (0.0)

1 (0.4)

0 (0.0)

2 (0.2)

 

 Asian

1 (0.3)

2 (0.7)

1 (0.4)

0 (0.0)

4 (0.4)

 

 Black or African American

102 (34.6)

100 (34.2)

94 (33.6)

47 (33.1)

343 (34.0)

 

 Multiple

6 (2.0)

1 (0.3)

6 (2.1)

1 (0.7)

14 (1.4)

 

 Native Hawaiian or Other Pacific Islander

2 (0.7)

1 (0.3)

1 (0.4)

1 (0.7)

5 (0.5)

 

 White

183 (62.0)

188 (64.4)

177 (63.2)

93 (65.5)

641 (63.6)

 

Weight (kg), mean (SD)

81.4 (20.8)

81.4 (20.4)

83.3 (19.2)

82.7 (21.9)

82.1 (20.4)

0.622

Duration of Lifetime Illness , years, mean (SD)

14.5 (10.7)

14.6 (10.7)

15.6 (11.0)

15.2 (10.4)

14.9 (10.7)

0.607

Number of Past Psychiatric Hospitalizations, mean (SD)

8.0 (9.4)

7.2 (7.3)

8.2 (8.8)

7.4 (5.7)

7.8 (8.2)

0.439

Simpson-Angus Total Score, mean (SD)

0.5 (1.4)

0.4 (1.2)

0.5 (1.9)

0.6 (1.7)

1.5 (1.5)

0.718

Barnes Akathisia Global Score, mean (SD)

0.1 (0.5)

0.1 (0.5)

0.1 (0.4)

0.1 (0.4)

0.1 (0.5)

0.799

AIMS 1–7 Total Score, mean (SD)

0.4 (1.2)

0.2 (1.1)

0.6 (2.0)

0.2 (1.0)

0.4 (1.4)

0.027

Efficacy-Evaluable ITT Population

N = 267

N = 267

N = 253

N = 132

N = 919

 

PANSS Total Score, mean (SD)

84.3 (14.8)

83.7 (14.0)

84.2 (14.5)

84.0 (16.2)

84.1 (14.7)

0.971

  1. Abbreviations: AIMS Abnormal Involuntary Movement Scale, ITT intent-to-treat, kg kilogram, n/N number of patients, PANSS Positive and Negative Syndrome Scale, SD standard deviation.
  2. Groups: PBO = placebo; LY40 = LY2140023 monohydrate 40 mg; LY80 = LY2140023 monohydrate 80 mg; RIS = risperidone.